Barclays PLC Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Barclays PLC grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 159.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 206,108 shares of the biopharmaceutical company's stock after purchasing an additional 126,562 shares during the quarter. Barclays PLC owned approximately 0.22% of Ultragenyx Pharmaceutical worth $8,671,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock valued at $422,167,000 after purchasing an additional 89,389 shares during the period. Invesco Ltd. grew its position in shares of Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock worth $71,509,000 after acquiring an additional 25,487 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Ultragenyx Pharmaceutical by 5.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock valued at $68,487,000 after acquiring an additional 81,667 shares during the period. Pictet Asset Management Holding SA boosted its stake in Ultragenyx Pharmaceutical by 125.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock worth $49,375,000 after purchasing an additional 653,088 shares during the period. Finally, Norges Bank acquired a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at $40,463,000. Institutional investors and hedge funds own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

RARE stock traded up $0.12 during midday trading on Tuesday, hitting $38.10. 51,523 shares of the stock were exchanged, compared to its average volume of 814,253. The stock's 50-day moving average price is $37.79 and its 200-day moving average price is $43.54. The stock has a market cap of $3.58 billion, a price-to-earnings ratio of -5.98 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RARE. Piper Sandler dropped their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. JPMorgan Chase & Co. boosted their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Wedbush reaffirmed a "neutral" rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, HC Wainwright restated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $92.79.

Insider Activity

In related news, EVP Thomas Richard Kassberg sold 6,028 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the sale, the executive vice president now owns 265,238 shares of the company's stock, valued at $11,166,519.80. This trade represents a 2.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now directly owns 54,991 shares of the company's stock, valued at $2,358,014.08. The trade was a 5.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,643 shares of company stock worth $5,256,268 over the last ninety days. 5.50% of the stock is currently owned by insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.